Cargando…

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer

Mutations in the promoter of the human Telomerase Reverse Transcriptase (hTERT) gene are common and associated with its elevated expression in bladder cancer, melanoma, and glioblastoma. Though these mutations and TERT overexpression are associated with aggressive disease and poor outcome, an incomp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Neeraj, Zhou, Qiong, Arya, Deepak, Rinaldetti, Sébastien, Duex, Jason, LaBarbera, Daniel V., Theodorescu, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501578/ https://www.ncbi.nlm.nih.gov/pubmed/36142729 http://dx.doi.org/10.3390/ijms231810819

Ejemplares similares

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes
por: Rinaldetti, Sébastien, et al.
Publicado: (2022)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics
por: Duex, Jason E., et al.
Publicado: (2021)

Targeted Long-Read Bisulfite Sequencing Identifies Differences in the TERT Promoter Methylation Profiles between TERT Wild-Type and TERT Mutant Cancer Cells
por: Lee, Seungjae, et al.
Publicado: (2022)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487
por: Heathcote, Helen R., et al.
Publicado: (2016)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers
por: Stern, Josh Lewis, et al.
Publicado: (2015)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer
por: Esquer, Hector, et al.
Publicado: (2021)

Angular analysis of $ {B}^0\to {D}^{\ast -}{D}_s^{\ast +} $ with $ {D}_s^{\ast +}\to {D}_s^{+}\gamma $ decays
por: Aaij, Roel, et al.
Publicado: (2021)

AST: Activity-Security-Trust driven modeling of time varying networks
por: Wang, Jian, et al.
Publicado: (2016)

Test of HQET with B^\ast, B^\ast \ast and lifetime measurements of B_s mesons and beauty baryons at DELPHI
por: Siccama, I
Publicado: (1995)

SAT-487 Unusual Case of Plurihormonal Pituitary Macroadenoma
por: Allehaibi, Ebtesam, et al.
Publicado: (2019)

ODP487 Iatrogenic Thyroid Storm Treated with Plasmapheresis
por: Alam, Mustafa, et al.
Publicado: (2022)

RET kinase alterations in targeted cancer therapy
por: Liu, Xuan, et al.
Publicado: (2020)

487 Safety of Sublingual Immunotherapy with Standardized Vaccines of Domestic Mites
por: Alvarez, Mirta, et al.
Publicado: (2012)

P487 Basidiobolus omanensis, an emerging pathogen to watch out for?
por: Al-hatmi, Abdullah, et al.
Publicado: (2022)

First Observation of the B ^\ast Dalitz Decay B ^\ast -> B\ e ^+ e ^-
por: DELPHI Collaboration
Publicado: (2018)

Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum
por: Borde, Kalyani, et al.
Publicado: (2022)

Exam ref 70-487: developing Windows Azure and web services
por: Ryan, William, et al.
Publicado: (2013)

AST Six Pack Premium
por: Basson, Craig Todd
Publicado: (1987)

$R(D^\ast)$ status
por: Wormser, Guy Henri Maurice
Publicado: (2017)

CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)
por: Oldenburg, Darby, et al.
Publicado: (2016)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors
por: Ferreira, Rubén, et al.
Publicado: (2015)

Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
por: Jordan, Allan M., et al.
Publicado: (2016)

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
por: Mahato, Arun Kumar, et al.
Publicado: (2020)

FOXM1 predicts disease progression in non-muscle invasive bladder cancer
por: Rinaldetti, Sebastien, et al.
Publicado: (2018)

Occipital intermittent rhythmic delta activity (OIRDA) in pediatric focal epilepsies: A case series
por: LaBarbera, Vincent, et al.
Publicado: (2021)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

B, D spectroscopy and \bar B-> D/D ^\ast /D ^\ast\astl\bar\nu
por: Bloch, D
Publicado: (1995)

SAT-487 Untreated Primary Hypothyroidism Presenting as Pica with Concurrent Hyponatremia and Rhabdomyolysis
por: Mirza, Mehwish A, et al.
Publicado: (2020)

487. Patient Outcomes of Contact Tracing for COVID-19 in a Pediatric Hospital
por: Smathers, Sarah, et al.
Publicado: (2020)

Structure basis for the modulation of CXC chemokine receptor 3 by antagonist AMG487
por: Jiao, Haizhan, et al.
Publicado: (2023)

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway
por: Lin, Chen, et al.
Publicado: (2016)

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
por: Elisei, Rossella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d4u1vp4n1m8j467sp3dcgn4ac6